RSVpreF cuts RSV-related respiratory hospitalizations ~70% versus no vaccine in expanded ESC 2026 follow-up.
Why the trial?
RSV infection in older adults triggers both respiratory and cardiovascular hospitalisations, but whether RSV vaccination prevents these cardiorespiratory events had not been demonstrated in a randomised trial powered for clinical outcomes.
Does bivalent RSVpreF vaccine prevent RSV-related respiratory hospitalization in adults?
Population
Adults >=60 (2025 primary cohort) plus a broader adult cohort; N not reported
Comparison
Bivalent RSVpreF vaccine vs no vaccine
Design
Pragmatic randomized trial (ESC 2026: expanded follow-up of the 2025 NEJM primary)
Key result
Expanded DAN-RSV follow-up at ESC 2026: RSVpreF cut RSV-related respiratory hospitalizations versus no vaccine (0.16 vs 0.55 per 1000 person-years; ~70% vaccine effectiveness).
Authors
Discussion
Key questions
No takes yet. Share an insight, caveat, or question.
Where experts stand
Experts broadly view DAN-RSV's ~70% vaccine effectiveness against RSV-related hospitalizations as strong real-world evidence, though some flag low absolute event rates and an unresolved signal in all-cause deaths.
Most clinicians reacting to DAN-RSV read it as compelling pragmatic evidence that RSV vaccination protects older adults, with particular relevance for those with cardiovascular disease. One voice questions whether the impressive relative reduction matters as much given very low absolute event rates, and highlights a numerically higher death count in the vaccine group. The live questions are whether this will drive broader uptake among cardiologists, how long protection lasts, and whether the all-cause mortality imbalance warrants further scrutiny.
Agreement
Multiple clinicians emphasize that RSV vaccination in older adults carries meaningful cardiovascular relevance, framing respiratory virus prevention as a strategy to reduce cardiorespiratory hospitalizations in patients with preexisting heart disease.
4 clinicians say this directly
Main debate
Strong relative vaccine efficacy versus very low absolute event rates and an unexplained mortality imbalance
Striking pragmatic evidence2
A 70% reduction in RSV-related hospitalization in a massive real-world trial is a convincing signal for broader vaccination.vs
Low absolute risk, mortality signal1
With vanishingly few RSV events in both groups and a numerically higher all-cause death rate in the vaccine arm, the clinical significance deserves scrutiny.Not placed5 reporting, watching, or context only
What they’re arguing about
supportiveneutralcautiouscritical
Counts are expert takes we classified by axis. Tap a row to see the takes behind its count.
Still unclear
The optimal revaccination interval remains unknown, as one commentator notes. The numerical imbalance in all-cause deaths (146 vs 120) flagged by one expert has not been addressed by the trial investigators in these posts. Whether these data will prompt guideline bodies to recommend RSV vaccination specifically for cardiovascular patients is an open question.
Key expert perspectives
Very low absolute event rates and a worrying mortality signal temper the headline efficacy
Points out that RSV events were rare in both groups (0.11 vs 0.37 events per 1000 person-years in the original cohort) and flags that all-cause deaths were numerically higher in the vaccine group (146 vs 120), calculating an RR of 1.22 (0.96-1.55).
Distilled from their postX post
RSV vaccination is an underutilized, cheap way to protect cardiovascular patients
Argues that DAN-RSV provides clear data showing cardiovascular patients are at risk from RSV hospitalization, calling vaccination an underutilized and inexpensive protective strategy.
Distilled from their postX post
TBTor Biering-SørensenCardiologist, Copenhagen University Hospital-GentoftePractice takeBefore results
Results support broader consideration of RSV vaccination in older adults with cardiovascular disease
States that the findings suggest potential downstream cardiorespiratory benefits and support including patients with CVD in RSV vaccination strategies to reduce severe complications.
Distilled from their postOriginal post
Overview
Supports RSVpreF vaccination in older adults with CVD; extends efficacy data to cardiorespiratory hospitalization prevention.
Key Points
- To assess the efficacy and safety of the bivalent RSV prefusion F (RSVpreF) vaccine in preventing RSV-related hospitalizations among adults.
- Pragmatic, open-label, randomized trial (NCT06684743) conducted in Denmark and Spain across the 2024–2025 and 2025–2026 winter seasons.
- A total of 513,358 adults (initially ≥60 years old in Denmark, expanded to ≥18 years old in Denmark and Spain) were randomly assigned in a 1:1 ratio to receive RSVpreF or no vaccine.
- The primary endpoint was RSV-related respiratory tract disease (RTD) hospitalization in the intention-to-treat population, with secondary endpoints evaluating RSV-related lower RTD and all-cause RTD hospitalizations.
- RSV-related RTD hospitalization occurred at 0.16 events per 1000 person-years in the RSVpreF group compared to 0.55 per 1000 person-years in the control group, representing a vaccine effectiveness of 70.3% (95% CI, 49.7–83.2).
- Incidence of RSV-related lower RTD hospitalization was 0.11 versus 0.39 events per 1000 person-years, reflecting a vaccine effectiveness of 71.1% (95% CI, 45.4–85.7), whereas all-cause RTD hospitalization was 11.16 versus 12.01 per 1000 person-years with a vaccine effectiveness of 7.1% (95% CI, -0.3–13.9).
- Serious adverse events occurred at similar rates across trial arms, affecting 2.0% of participants in the RSVpreF group and 2.2% in the no-vaccine group.
Evidence details
What drove the result?
| Outcome | RSVpreF | No vaccine |
|---|---|---|
| RSV respiratory hospitalization, adults >=60 (2025 primary) | 0.11 | 0.66 |
| Per 1000 participant-years; 83.3% vaccine effectiveness (2025 NEJM primary) | ||
| RSV respiratory hospitalization, expanded cohort | 0.16 | 0.55 |
| Per 1000 person-years; ~70% effectiveness in ESC 2026 expanded follow-up incl. broader adult cohort | ||
Limitations & tradeoffs
Design limitations
the ESC 2026 readout is an expanded follow-up without a new results paper; the 2025 NEJM publication remains the primary source.
Statistical certainty
cohort sizes, confidence intervals, and follow-up duration are not reported in the record.
Structured PICO
Does bivalent RSVpreF vaccine prevent RSV-related respiratory hospitalization in adults?
P
Population
Adults ≥60 years of age evaluated for the prevention of RSV-related respiratory hospitalization.
I
Intervention
Bivalent RSVpreF vaccine
C
Comparator
No vaccine
O
Outcome
RSV-related respiratory hospitalizationhard clinical
Main Result
Effect estimate: 83.3% vaccine effectiveness
Absolute Event Rate: 0.11% vs 0.66%
The bivalent RSVpreF vaccine significantly reduces RSV-related respiratory hospitalizations in older adults and broader adult cohorts.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Lassen et al. (2026) conducted an RCT in RSV. Bivalent RSVpreF vaccine vs. No vaccine was evaluated on RSV-related respiratory hospitalization (83.3% vaccine effectiveness). Expanded DAN-RSV follow-up at ESC 2026: RSVpreF cut RSV-related respiratory hospitalizations versus no vaccine (0.16 vs 0.55 per 1000 person-years; ~70% vaccine effectiveness).